ENDURANCE-3: safety and efficacy of glecaprevir/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-naïve HCV genotype 3-infected patients without cirrhosis-Reference-Cited by-同舟云学术

ENDURANCE-3: safety and efficacy of glecaprevir/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-naïve HCV genotype 3-infected patients without cirrhosis

Published:2017 Issue:1 Volume:66 Page:S33
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Foster G.R.,Gane E.,Asatryan A.,Asselah T.,Ruane P.J.,Pol S.,Poordad F.,Stedman C.A.,Dore G.,Roberts S.K.,Kaita K.,Vierling J.,Vargas H.E.,Kort J.,Lin C.-W.,Liu R.,Ng T.,Mensa F.

Publisher

Elsevier BV

Subject

Hepatology

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GRAND PLAN: Safety and Efficacy of Glecaprevir/Pibrentasvir for the Treatment of Hepatitis C Virus Infection Among People Initially Disengaged From Health Care Who Use Drugs—A Systematic Multidisciplinary Approach;Open Forum Infectious Diseases;2024-02-29

2. SASLT guidelines: Update in treatment of hepatitis C virus infection, 2024;Saudi Journal of Gastroenterology;2024-01

3. Effectiveness of Glecaprevir/Pibrentasvir in Patients with Chronic HCV-infection Genotypes 1 to 6 in the real-world settings in Russia (EVEREST study);Journal Infectology;2023-07-06

4. Efficacy of generic sofosbuvir with daclatasvir compared to sofosbuvir/ledipasvir in genotype 4 hepatitis C virus: A prospective comparison with historical control;Health Science Reports;2022-12-08

5. Direct antiviral agents in hepatitis C virus related liver disease: Don’t count the chickens before they’re hatched;World Journal of Gastroenterology;2021-06-07